New York State Teachers Retirement System Sells 7,831 Shares of IQVIA Holdings Inc. (NYSE:IQV)

New York State Teachers Retirement System lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 147,038 shares of the medical research company's stock after selling 7,831 shares during the quarter. New York State Teachers Retirement System owned about 0.08% of IQVIA worth $25,923,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IQV. American National Bank & Trust bought a new position in IQVIA during the 1st quarter worth $26,000. Golden State Wealth Management LLC increased its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares during the period. ST Germain D J Co. Inc. raised its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in IQVIA during the fourth quarter worth about $39,000. Finally, Lee Danner & Bass Inc. acquired a new stake in IQVIA during the fourth quarter worth about $44,000. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 0.2%

NYSE IQV traded down $0.41 on Friday, reaching $164.24. The company had a trading volume of 674,106 shares, compared to its average volume of 1,651,146. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The firm has a market cap of $28.41 billion, a price-to-earnings ratio of 22.38, a P/E/G ratio of 1.83 and a beta of 1.30. The business has a 50 day moving average of $150.59 and a two-hundred day moving average of $173.51.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.54 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Truist Financial cut their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.